Prelude Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Prelude Therapeutics' es Kris Vaddi , nombrado en Feb 2016, tiene una permanencia de 8.17 años. compensación anual total es $3.30M, compuesta por 16.9% salario y 83.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.94% de las acciones de la empresa, por valor de $8.33M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 3.9 años, respectivamente.
Información clave
Kris Vaddi
Chief Executive Officer (CEO)
US$2.6m
Compensación total
| Porcentaje del salario del CEO | 21.7% |
| Permanencia del CEO | 8.3yrs |
| Participación del CEO | 3.9% |
| Permanencia media de la dirección | 2.4yrs |
| Promedio de permanencia en la Junta Directiva | 4yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 09
Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Feb 03Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Sep 17We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 28Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Jan 28We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
Oct 27Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Oct 18Prelude downgraded at Morgan Stanley ahead of key update
Sep 09We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Jun 28Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Mar 14We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
Dec 14Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Jul 05What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?
Feb 16
Prelude Therapeutics prices $150M share offering
Jan 07Prelude Therapeutics readies public offering
Jan 04Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares
Dec 25Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$126m |
| Dec 31 2023 | US$3m | US$573k | -US$122m |
| Sep 30 2023 | n/a | n/a | -US$117m |
| Jun 30 2023 | n/a | n/a | -US$117m |
| Mar 31 2023 | n/a | n/a | -US$114m |
| Dec 31 2022 | US$3m | US$558k | -US$115m |
| Sep 30 2022 | n/a | n/a | -US$120m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$7m | US$544k | -US$112m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$69m |
| Dec 31 2020 | US$12m | US$417k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$32m |
| Dec 31 2019 | US$2m | US$315k | -US$28m |
Compensación vs. Mercado: La compensación total de Kris($USD3.30M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.60M).
Compensación vs. Ingresos: La compensación de Kris ha sido consistente con los resultados de la empresa en el último año.
CEO
Kris Vaddi (57 yo)
8.3yrs
Permanencia
US$2,641,789
Compensación
Dr. Krishna Vaddi, D.V.M., Ph D., also known as Kris, founded Prelude Therapeutics Incorporated and serves as its Chief Executive Officer and Director from February 2016. He has been its Chief Executive Of...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 8.3yrs | US$2.64m | 3.94% $ 8.8m | |
| President & Chief Medical Officer | 2.1yrs | US$1.65m | 0.093% $ 208.7k | |
| Interim CFO | 1.3yrs | US$1.67m | 0.0044% $ 9.8k | |
| Senior VP and Head of Strategic Planning & Operations | 2.3yrs | sin datos | sin datos | |
| Senior Vice President of Technical Operations | 3.3yrs | sin datos | sin datos | |
| Chief Scientific Officer | 6.1yrs | US$1.63m | 0.33% $ 735.4k | |
| Vice President of Investor Relations | no data | sin datos | sin datos | |
| Chief People Officer | 2.9yrs | sin datos | sin datos | |
| Executive VP & Chief Chemistry Officer | 5.1yrs | US$2.63m | 0.57% $ 1.3m | |
| Senior Vice President of Translation Medicine | 2.4yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 1.7yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 1.6yrs | sin datos | sin datos |
2.4yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de PRLD se considera experimentado (2.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 8.3yrs | US$2.64m | 3.94% $ 8.8m | |
| Independent Director | 3.3yrs | US$140.03k | 0% $ 0 | |
| Independent Chairman of the Board | 7.8yrs | US$161.03k | 0.91% $ 2.0m | |
| Independent Director | 2.8yrs | US$134.53k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$144.53k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$147.03k | 0.018% $ 40.7k | |
| Independent Director | 4yrs | US$131.03k | 0% $ 0 |
4.0yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de PRLD se considera experimentada (3.9 años de antigüedad promedio).